FDA Device

Clinical Chemistry Phosphorus in vitro diagnostic, List Number: 7D71-30 and 7D71-20

Hazard

Patient results are falsely decreased by up to 15% at these levels: 1) Serum Plasma phosphorus greater than 8.0 mg/dL (2.60 mmol/L) 2) Urine phosphorus greater than 80.0 mg/dL (25.80 mmol/L)

What You Should Do

Remedy

A Product Correction letter dated January 30, 2007 provided to all Clinical Chemistry Phosphorus customers that have received lot numbers 42020HW00 and 44037HW00 stating that patient results are falsely decreased by up to 15% at these levels: Serum/Plasma phosphorus greater than 8.0 mgldL (2.60 mmol/L) and Urine phosphorus greater than 80.0 mg/dl. (25.80 mmol/L). Modified linearity ranges are provided in the letter that are to be implemented when using the two lots. Instructions are also provided for changing the linearity range on the Architect cSystem as well as the Aeroset System. Customers are instructed that If they have forwarded any of Information the Clinical Chemistry Phosphorus lots listed above to another laboratory to provide a copy of this letter to them. A customer response form is provided.

Products

Clinical Chemistry Phosphorus in vitro diagnostic, List Number: 7D71-30 and 7D71-20
Brand
Abbott Laboratories Inc.
UPC
42020HW00 & 44037HW00

Units Affected

42020HW00 - 1,351 units worldwide; 44037HW00 - 314 units worldwide